GHLF has just released a User’s Guide to the Healthcare System. Included are explanations of common insurance barriers, tools for communicating with your provider’s office, information on how patients can become advocates, and more. Learn more below: https://www.everydayhealth.com/public-health/users-guide-healthcare-system-launches-today/ https://thedoctorweighsin.com/the-modern-patient-needs-to-be-an-expert-insurance-navigator/

Global Healthy Living Foundation’s Director of State and National Advocacy, Stephen Marmaras, recently was interviewed on the radio in Alaska to discuss recent biosimilar legislation and its implications for Alaskans.

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

Imagine you’ve been living with rheumatoid arthritis for more than ten years.

The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.

Director, State and National Advocacy Stephen Marmaras speaks with David Lile on Columbia Morning on House Bill 1366

Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.

Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.